 |
|
Clinical Outcomes Following Institution of Universal Leukoreduction of Blood Transfusions for Premature Infants
Dean Fergusson, MHA;
Paul C. Hébert, MD, MHSc;
Shoo K. Lee, MBBS, PhD;
C. Robin Walker, MBChB;
Keith J. Barrington, MBChB;
Lawrence Joseph, PhD;
Morris A. Blajchman, MD;
Stan Shapiro, PhD
JAMA. 2003;289:1950-1956.
Context Leukocytes present in stored blood products can have a variety of biological effects, including depression of immune function, thereby increasing nosocomial infections and possibly resulting in organ failure and death. Premature infants, given their immature immune state, may be uniquely predisposed to the effects of transfused leukocytes.
Objective To evaluate the clinical outcomes following implementation of a universal prestorage red blood cell (RBC) leukoreduction program in premature infants admitted to neonatal intensive care units (NICUs).
Design and Setting Retrospective before-and-after study conducted in 3 Canadian tertiary care NICUs from January 1998 to December 2000.
Patients A total of 515 premature infants weighing less than 1250 g who were admitted to the NICU, received at least 1 RBC transfusion, and survived at least 48 hours were enrolled. The intervention group consisted of infants admitted in the 18-month period following the introduction of universal leukoreduction (n = 247) and the control group consisted of infants admitted during the 18 months prior to the introduction of universal leukoreduction (n = 268).
Main Outcome Measures Primary outcomes were nosocomial bacteremia and NICU mortality, compared before and after implementation of universal leukoreduction using multivariate regression. Secondary outcomes included bronchopulmonary dysplasia, retinopathy of prematurity, necrotizing enterocolitis, and intraventricular hemorrhage.
Results The proportion of infants who acquired bacteremia after an RBC transfusion was 79/267 (29.6%) in the nonleukoreduction period and 63/246 (25.6%) in the leukoreduction period. For NICU mortality, there were 45 deaths (16.8%) in the nonleukoreduction period and 44 deaths (17.8%) in the leukoreduction period. The adjusted odds ratio (OR) for bacteremia was 0.59 (95% confidence interval [CI], 0.34-1.01) and for mortality was 1.22 (95% CI, 0.59-2.50). The adjusted ORs for bronchopulmonary dysplasia and retinopathy of prematurity were 0.42 (95% CI, 0.25-0.70) and 0.56 (95% CI, 0.33-0.93), respectively. The adjusted ORs for necrotizing enterocolitis and grade 3 or 4 intraventricular hemorrhage were 0.39 (95% CI, 0.17-0.90) and 0.65 (95% CI, 0.35-1.19), respectively. The adjusted OR for a composite measure of any major neonatal morbidity was 0.31 (95% CI, 0.17-0.56). Crude and adjusted rates for all secondary outcomes suggest that leukoreduction was associated with improved outcomes.
Conclusion Implementation of universal prestorage leukoreduction was not associated with significant reductions in NICU mortality or bacteremia but was associated with improvement in several clinical outcomes in premature infants requiring RBC transfusions.
Author Affiliations: Departments of Epidemiology and Biostatistics (Mr Fergusson and Drs Joseph and Shapiro) and Pediatrics (Dr Barrington), McGill University, Montreal, Quebec; University of Ottawa Centre for Transfusion Research, Ottawa Hospital (Mr Fergusson and Dr Hèbert), Clinical Epidemiology Unit, Ottawa Health Research Institute (Mr Fergusson and Dr Hébert), and Department of Pediatrics, University of Ottawa (Dr Walker), Ottawa, Ontario; Department of Pediatrics, University of British Columbia, Vancouver (Dr Lee); and Department of Pathology, McMaster University Medical Center, and Canadian Blood Services, Hamilton, Ontario (Dr Blajchman).
RELATED ARTICLES
Clinical Outcomes Following Institution of the Canadian Universal Leukoreduction Program for Red Blood Cell Transfusions
Paul C. Hébert, Dean Fergusson, Morris A. Blajchman, George A. Wells, Andrew Kmetic, Doug Coyle, Nancy Heddle, Marc Germain, Mindy Goldman, Baldwin Toye, Irwin Schweitzer, Carl vanWalraven, Dana Devine, and Graham D. Sher
JAMA. 2003;289(15):1941-1949.
ABSTRACT
| FULL TEXT
Is Leukoreduction of Blood Components for Everyone?
Howard L. Corwin and James P. AuBuchon
JAMA. 2003;289(15):1993-1995.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Controversies in RBC Transfusion in the Critically Ill
Hebert et al.
Chest 2007;131:1583-1590.
ABSTRACT
| FULL TEXT
Transfusion Strategies for Patients in Pediatric Intensive Care Units
Lacroix et al.
NEJM 2007;356:1609-1619.
ABSTRACT
| FULL TEXT
Hazards of Neonatal Blood Transfusion
Galel and Fontaine
NeoReviews 2006;7:e69-e75.
FULL TEXT
Therapeutic Techniques: Selection of Blood Components for Neonatal Transfusion
Galel
NeoReviews 2005;6:e351-e355.
FULL TEXT
Evidence-Based Medicine in the ICU: Important Advances and Limitations
Vincent
Chest 2004;126:592-600.
ABSTRACT
| FULL TEXT
Effects of transfusion with red cells filtered to remove leucocytes: randomised controlled trial in patients undergoing major surgery
van Hilten et al.
BMJ 2004;328:1281.
ABSTRACT
| FULL TEXT
Will we ever know if leukoreduction of red blood cells should be performed?/Saurons-nous un jour s'il faut proceder a la reduction leucocytaire des culots globulaires ?
Carson and Berlin
Canadian J. Anesthesia 2004;51:407-410.
FULL TEXT
Transfusion of leukoreduced red blood cells may decrease postoperative infections: two meta-analyses of randomized controlled trials: [La transfusion de sang reduit en leucocytes peut diminuer les infections postoperatoires : deux meta-analyses d'etudes randomisees et controlees]
Fergusson et al.
Canadian J. Anesthesia 2004;51:417-424.
ABSTRACT
| FULL TEXT
Is Leukoreduction of Blood Components for Everyone?
Corwin and AuBuchon
JAMA 2003;289:1993-1995.
FULL TEXT
|
